<DOC>
	<DOCNO>NCT00857766</DOCNO>
	<brief_summary>The purpose study evaluate patient Chronic Obstructive Pulmonary Disease ( COPD ) Advair DISKUS™ 250/50mcg BID modifies arterial stiffness measure associate risk heart disease .</brief_summary>
	<brief_title>A 16-Week Study Evaluate Effect Advair DISKUS™ 250/50mcg Arterial Stiffness Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo control study evaluate effect Fluticasone Propionate/Salmeterol DISKUS 250/50mcg ( FSC ) BID arterial stiffness COPD subject . Following 1 14 day run-in period , approximately 250 subject randomly assign double-blind treatment 12 week . After 12 week treatment period , subject treatment arm receive open label Tiotropium bromide Handihaler18mcg ( Tio ) QD 4 week addition continue study drug ( either FSC250/50 placebo ) . The primary measure efficacy Pulse Wave Velocity ( PWV ) Endpoint . Secondary efficacy measure include Augmentation Index ( AIx ) , Biomarkers cardiovascular disease , measure lung function . ( e.g . FEV1 ) . Safety assess collection adverse event COPD exacerbation . Exploratory endpoint include effect Tiotropium PWV AIx add placebo FSC . Treatment group stratify base current smoking status . There total 6 study visit ( screen , randomization , 4 , 8 , 12 16 week treatment ) . A follow-up phone contact collection adverse event pregnancy information ( applicable ) conduct approximately 14 day follow last study visit .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Signed date write informed consent obtain subject and/or subject 's legally acceptable representative prior study participation . Males female great equal 50 year age . A postalbuterol FEV1/FVC ratio &lt; equal 0.70 A postalbuterol FEV1 &lt; 80 % predict normal . Patients current fomer smoker must cigarette smoke history &gt; great equal 10 packyears . A current diagnosis asthma A body mass index ( BMI ) &gt; equal 35kg/m2 A respiratory diagnosis COPD ( e.g. , lung cancer , bronchiectasis , sarcoidosis , tuberculosis , lung fibrosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>Computed Tomography</keyword>
	<keyword>pulse wave velocity</keyword>
	<keyword>Pulse wave analysis</keyword>
</DOC>